Rob Miani joined the MMRF team as Chief Financial Officer in 2016. Most recently he was the Vice President of Finance and Corporate Controller of Aptuit, LLC, a global contract research organization providing integrated early discovery to mid-phase drug development services in the pharmaceutical industry. Rob has over 20 years of leadership experience in the private and public sectors, holding managerial positions in the renewable energy, private equity, Internet and technology industries, including Davenport Newberry, Oak Investment Partners and INT Media Group. He began his career with Arthur Anderson LLP in the Assurance and Business Advisory Services Division. Rob is a CPA and received his BS degree in Accounting from Fairfield University.
The MMRF CoMMpass Study℠ Data Jamboree 2016
The MMRF CoMMpass Study℠ Data Jamboree 2016
Held in Cambridge, Massachusetts, the MMRF invited over 40 attendees from various organizations to attend the MMRF CoMMpass Study Data Jamboree to discuss new findings and next steps related to the landmark CoMMpass Study℠, an initiative which is changing how researchers think about using data to drive actionable insights in the clinic.
In a heterogeneous disease such as multiple myeloma, data generation, sharing and analysis coupled with broad collaboration are essential tools to speed progress. Robust efforts are needed to build bridges, foster cooperation and share ideas between the pharmaceutical industry, academic research centers and community oncologists. It is only by working together that we can aggregate enough data to do meaningful analysis – especially when studying many different multiple myeloma subtypes. No single organization can do it alone.
The Multiple Myeloma Research Foundation (MMRF) CoMMpass Study℠ Data Jamboree 2016 exemplifies this approach. Held in Cambridge, Massachusetts, the MMRF invited over 40 attendees from various nonprofit, academic and pharmaceutical organizations to discuss new findings and next steps related to the landmark CoMMpass Study℠, an initiative which is changing how researchers think about using data to drive actionable insights in the clinic.
WATCH VIDEO
CoMMpass, the cornerstone of the MMRF’s Precision Medicine Initiative, is a prospective, longitudinal, observational study capturing the largest genomic data set in multiple myeloma. This study follows 1,000 patients throughout the course of their disease. By mapping each patient’s genomic profiles to clinical outcomes, CoMMpass is enabling precision medicine in multiple myeloma patients – delivering the right treatment at the right time.
CoMMpass is the largest, deepest, most robust data set in the field of multiple myeloma.
Representatives from CoMMpass’ participating organizations regularly meet to review the maturing data, explore trends and consider new hypotheses. Preliminary findings from CoMMpass have already provided insight into clinical questions of great importance to patients – Should I be on triplet or doublet-based initial therapy? Should I have a stem cell transplant? Is my genomic profile predicitive?
Participants in the CoMMpass Data Jamboree 2016 discussed recent findings to further understand the characteristics of newly diagnosed patients with multiple myeloma. Future questions that we need to address include better ways to measure response to treatment, predictors of response and drug-related toxicities. We also need to develop the most appropriate molecular tests and study the potential role of immune system in treating multiple myeloma.
Moving forward, the MMRF and CoMMpass stakeholders are committed to continued collaboration, data sharing and the use of broad, cutting-edge technology in order to advance precision medicine – with the ultimate goal of improving the lives of patients with multiple myeloma.
